Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 20/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6750757 | 0.88 | SLC16A1 (0.75) | SLC16A1CYP2C9CYP3A4 | |
| SCHEMBL6343258 | 0.87 | SLC16A1 (0.74) | SLC16A1CYP2C9CYP3A4 | |
| SCHEMBL6345554 | 0.87 | SLC16A1 (0.75) | SLC16A1CYP2C9 | |
| SCHEMBL6340735 | 0.87 | SLC16A1 (0.73) | SLC16A1CYP2C9CYP3A4 | |
| SCHEMBL6642119 | 0.86 | SLC16A1 (0.70) | SLC16A1CYP2C9 | |
| SCHEMBL4802041 | 0.86 | SLC16A1 (0.82) | SLC16A1CYP2C9CYP3A4 | |
| SCHEMBL6344750 | 0.84 | SLC16A1 (0.71) | SLC16A1CYP2C9CYP3A4 | |
| SCHEMBL6355143 | 0.83 | SLC16A1 (0.68) | SLC16A1CYP2C9 | |
| SCHEMBL6352487 | 0.83 | SLC16A1 (0.75) | SLC16A1CYP2C9CYP3A4 | |
| SCHEMBL6353557 | 0.83 | SLC16A1 (0.68) | SLC16A1CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-7361660-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2008-04-22 | — | — | US | disclosed |
| EP-1412362-B1 | THIENO¬2,3-d|PYRIMIDINEDIONES AS INHIBITORS OF T-CELLS PROLIFERATION | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-6890923-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-05-10 | — | — | US | disclosed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| US-20040171623-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
| EP-1280806-B1 | THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2004-08-04 | — | — | EP | disclosed |
| US-20040122028-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | US | disclosed |
| US-20040014634-A1 | Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014634-A1 | Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals | DPYD, TYMP, TYMS | SLC16A1 4584/4885CYP2C9 126/4885CYP3A4 188/4885 |
| US-20040171623-A1 | Chemical compounds | CBR1, SETDB1, CBR3 | SLC16A1 1397/4885CYP2C9 63/4885CYP3A4 60/4885 |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | TPMT, CBR1, CYP2D6 | SLC16A1 3284/4885CYP2C9 89/4885CYP3A4 93/4885 |
| US-20040122028-A1 | Novel compounds | DPYD, TYMS, TYMP | SLC16A1 4709/4885CYP2C9 203/4885CYP3A4 160/4885 |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | C5, TPMT, C9 | SLC16A1 3369/4885CYP2C9 71/4885CYP3A4 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.